Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary ...Middle East

SAN FRANCISCO and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent delivers oral presentation on clinical data of ibi363 first in class pd 1 il 2a bias bispecific antibody fusion protein in advanced non small cell lung cancer and other solid tumors at the 2024 esmo virtual plenary was published today ( Friday 14/06/2024 - 03:44 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary )

Also on site :

• The essentials in your ‘big shop’ set to cost even more thanks to the energy crisis
• Researchers let AI models run a simulated society. Claude was the safest—and Grok committed 180 crimes and went extinct within 4 days
• 1975 Rock Song, Lasting Nearly 9 Minutes, Became an Overshadowed Classic